The Biz Reporter
Mumbai: Shares of Lupin Ltd were trading around ₹2,108, keeping investors cautious as the stock hovers close to a critical long-term support zone defined by its 200-day exponential moving average (EMA) and valuation benchmarks.
Market participants tracking technical indicators note that Lupin’s price is near, but slightly above, its 200-day EMA, a level often viewed as a dividing line between long-term strength and weakness. Analysts say this positioning suggests the broader uptrend remains intact, though near-term momentum appears muted.
Key Buying Levels in Focus
According to technical and valuation-based analysis, investors are eyeing two important accumulation zones:
- ₹2,050–₹2,000:
This range aligns closely with the 200-day EMA, offering what analysts describe as the best risk–reward zone for medium- to long-term investors. - ₹1,950–₹1,900:
A deeper support area that coincides with a long-term demand zone and sits clearly below the stock’s so-called “golden valuation line”, making it attractive for patient, value-oriented buyers.
At the current price of ₹2,108, market experts advise against aggressive fresh buying. Instead, investors are recommended to either wait for a dip or initiate only a small starter position, keeping capital ready for lower levels.
Valuation Signals Remain Mixed
Lupin is currently trading below its fair-value growth trajectory, often referred to by analysts as the golden valuation line. This typically indicates that while the company’s growth outlook remains intact, the stock may require either time or a mild correction before justifying higher prices.
Outlook
On the upside, analysts see potential for the stock to move towards the ₹2,350–₹2,600 range over the next 12–24 months, supported by improving margins, a stabilising US generics business, and steady domestic performance. However, a sustained break below ₹1,880 on a weekly closing basis could weaken the long-term setup and prompt a reassessment.
Investor Takeaway
Lupin is not viewed as overvalued, but experts caution that selective, staggered buying is the preferred strategy at current levels rather than lump-sum investments. For now, the stock remains firmly on investors’ watchlists as it tests crucial technical and valuation thresholds.
